Durvalumab Earns Priority Review, Breakthrough Status in Gastric Cancer
Results from the phase 3 MATTERHORN trial support the FDA’s designations for durvalumab in gastric/gastroesophageal junction cancers.
Key Advances Across Kidney Cancer Research and Management at KCRS 2025
Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.
Early-Stage Kidney Cancer Trial Aims to Restore Anti-Cancer Immunity
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Highlighting Beneficial Adjuvant/Neoadjuvant Strategies for Kidney Cancer
Although pembrolizumab addressed a long-standing need in adjuvant kidney cancer treatment, combinations with the agent may further bolster efficacy.
COCOON Regimen Shows Promise in Mitigating Dermatologic AEs During NSCLC Treatment
A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.
Belantamab Mafodotin Combo Has Meaningful Benefits in R/R Multiple Myeloma
Data from the DREAMM-7 trial may support belantamab mafodotin plus bortezomib and dexamethasone as a new standard of care in this patient population.
Breaking Down the Phase 2 LASER trial of 177Lu-PSMA-617 in Clear Cell RCC
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Applying Clinical Trials to Patient Cases: The Melanoma Landscape
Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.
177Lu-PSMA-617 Trial May Be Efficacious in Advanced PSMA-Expressing ccRCC
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes
Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.
Isatuximab Combo Approved in the EU for Transplant-Eligible NDMM
Results from the phase 3 GMMG-HD7 trial support the approval of the isatuximab-based combination in patients with newly diagnosed multiple myeloma.
Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer
Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.
Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC
Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.
Research Consortium Aims to Accelerate Progress in Kidney Cancer Management
Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.
EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET
Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.
Analyzing Natural Killer Cell Restoration/KIM-1 Biomarker in Kidney Cancer
A genitourinary oncologist explained that KIM-1 can be used diagnose, risk-stratify, detect, and monitor disease treatment in patients with kidney cancers.
Belantamab Mafodotin Combos Receive EU Approval for R/R Multiple Myeloma
Phase 3 DREAMM-7 and DREAMM-8 trial results showed that combinations with belantamab mafodotin showed superior efficacy vs standard of care in the disease.
Elironrasib Earns FDA Breakthrough Designation for KRAS G12C-Mutant NSCLC
The agency’s decision is based on results from the phase 1 RMC-6291-001 clinical trial evaluating elironrasib monotherapy in patients with solid tumors.
XmAb819 Targets Highly Expressed Protein in Clear Cell Renal Cell Carcinoma
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
Generic Ibrutinib Tablets Earn Tentative FDA Approval in Blood Cancers
Ibrutinib tablets will become available at 140 mg, 280 mg, and 420 mg for patients with chronic lymphocytic leukemia and Waldenström macroglobulinemia.
Inavolisib Combo Receives EU Approval in PIK3CA+ ER+/HER2– Breast Cancer
Data from the phase 3 INAVO120 trial support the approval of inavolisib-based treatment for patients with PIK3CA+, ER+/HER2– disease in the EU.
Novel CAR T-Cell Therapy Prioritizes Immune-Restoring Capability in RCC
“The therapy is designed to prevent CAR T-cell inactivation and to restore the antitumor immunity of the white blood cells that have gotten through the tumor,” said Wayne A. Marasco, MD, PhD.
DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC
Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.
EC Approves Ibrutinib Plus Chemoimmunotherapy +/- ASCT in Untreated MCL
Results from the phase 3 TRIANGLE trial showed prolonged failure-free survival and overall survival with ibrutinib and CIT vs CIT plus ASCT alone.
Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma
Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.
Pembrolizumab Combo Receives Canadian Approval in Cervical Cancer
Data from the phase 3 KEYNOTE-A18 trial support the approval of the pembrolizumab-based regimen for those with stage III to IVA cervical cancer in Canada.
European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL
Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Exploring Novel Therapeutic Combination Strategies in Kidney Cancer
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
A Decade of Research Led to Reduced Toxicity With Novel CAR T-Cell Therapy in RCC
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Novel Cancer Vaccine Combos Show Efficacy, Safety in Late-Stage Melanoma
The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.
![“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F9addaac21d809a7b642a567b0a704cbb15d87ac5-2966x1684.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.")
